SG11201407184PA - Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals - Google Patents
Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticalsInfo
- Publication number
- SG11201407184PA SG11201407184PA SG11201407184PA SG11201407184PA SG11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA SG 11201407184P A SG11201407184P A SG 11201407184PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceuticals
- preparing
- derivatives
- chromen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1737CH2012 | 2012-05-04 | ||
US201261671956P | 2012-07-16 | 2012-07-16 | |
PCT/IB2013/053544 WO2013164801A1 (en) | 2012-05-04 | 2013-05-03 | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407184PA true SG11201407184PA (en) | 2014-12-30 |
Family
ID=54193684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407184PA SG11201407184PA (en) | 2012-05-04 | 2013-05-03 | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
Country Status (25)
Country | Link |
---|---|
US (1) | US9309216B2 (zh) |
EP (1) | EP2844647B1 (zh) |
JP (2) | JP6290186B2 (zh) |
KR (1) | KR102073181B1 (zh) |
CN (2) | CN108084138A (zh) |
AP (1) | AP3547A (zh) |
AU (1) | AU2013255469B2 (zh) |
BR (1) | BR112014027470A2 (zh) |
CA (1) | CA2871000C (zh) |
CL (1) | CL2014002986A1 (zh) |
CO (1) | CO7141413A2 (zh) |
CY (1) | CY1123456T1 (zh) |
EA (1) | EA032812B1 (zh) |
HK (1) | HK1203964A1 (zh) |
IL (1) | IL235181A (zh) |
MX (1) | MX365250B (zh) |
MY (1) | MY171207A (zh) |
NZ (1) | NZ701198A (zh) |
PH (1) | PH12014502453A1 (zh) |
PL (1) | PL2844647T3 (zh) |
RS (1) | RS61035B1 (zh) |
SG (1) | SG11201407184PA (zh) |
SI (1) | SI2844647T1 (zh) |
WO (1) | WO2013164801A1 (zh) |
ZA (1) | ZA201407769B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2496567T3 (pl) | 2009-11-05 | 2018-01-31 | Rhizen Pharmaceuticals S A | Nowe benzopiranowe modulatory kinazy |
US10130635B2 (en) * | 2012-05-04 | 2018-11-20 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
EA032812B1 (ru) * | 2012-05-04 | 2019-07-31 | Ризен Фармасьютикалз Са | Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов |
BR112015030385B1 (pt) | 2013-06-07 | 2020-08-18 | Rhizen Pharmaceuticals S.A. | Composto, composto para uso e composição farmacêutica |
CA2951370A1 (en) * | 2014-06-27 | 2015-12-30 | Rhizen Pharmaceuticals Sa | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
EP3325462A4 (en) * | 2015-07-23 | 2019-06-19 | Pharmakea, Inc. | INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS |
JP2019508400A (ja) | 2016-02-09 | 2019-03-28 | ファーマケア,インク. | キノリノンリシルオキシダーゼ様2阻害剤とその使用 |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2023130334A1 (zh) * | 2022-01-07 | 2023-07-13 | 同润生物医药(上海)有限公司 | 一种色烯-4-酮化合物及其中间体的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62201882A (ja) * | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
PL2496567T3 (pl) * | 2009-11-05 | 2018-01-31 | Rhizen Pharmaceuticals S A | Nowe benzopiranowe modulatory kinazy |
SG194718A1 (en) * | 2011-05-04 | 2013-12-30 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinases |
EA032812B1 (ru) * | 2012-05-04 | 2019-07-31 | Ризен Фармасьютикалз Са | Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов |
ES2647416T3 (es) * | 2012-07-04 | 2017-12-21 | Rhizen Pharmaceuticals S.A. | Inhibidores de PI3K delta selectivos |
-
2013
- 2013-05-03 EA EA201491818A patent/EA032812B1/ru unknown
- 2013-05-03 AU AU2013255469A patent/AU2013255469B2/en not_active Ceased
- 2013-05-03 SG SG11201407184PA patent/SG11201407184PA/en unknown
- 2013-05-03 JP JP2015509560A patent/JP6290186B2/ja not_active Expired - Fee Related
- 2013-05-03 CN CN201810028555.5A patent/CN108084138A/zh active Pending
- 2013-05-03 PL PL13729095T patent/PL2844647T3/pl unknown
- 2013-05-03 NZ NZ701198A patent/NZ701198A/en not_active IP Right Cessation
- 2013-05-03 CA CA2871000A patent/CA2871000C/en not_active Expired - Fee Related
- 2013-05-03 CN CN201380023361.1A patent/CN104507922B/zh not_active Expired - Fee Related
- 2013-05-03 MX MX2014013426A patent/MX365250B/es active IP Right Grant
- 2013-05-03 AP AP2014008087A patent/AP3547A/xx active
- 2013-05-03 EP EP13729095.3A patent/EP2844647B1/en active Active
- 2013-05-03 KR KR1020147034065A patent/KR102073181B1/ko active IP Right Grant
- 2013-05-03 RS RS20201267A patent/RS61035B1/sr unknown
- 2013-05-03 MY MYPI2014003098A patent/MY171207A/en unknown
- 2013-05-03 US US14/398,902 patent/US9309216B2/en not_active Expired - Fee Related
- 2013-05-03 SI SI201331803T patent/SI2844647T1/sl unknown
- 2013-05-03 WO PCT/IB2013/053544 patent/WO2013164801A1/en active Application Filing
- 2013-05-03 BR BR112014027470A patent/BR112014027470A2/pt not_active Application Discontinuation
-
2014
- 2014-10-19 IL IL235181A patent/IL235181A/en active IP Right Grant
- 2014-10-24 ZA ZA2014/07769A patent/ZA201407769B/en unknown
- 2014-11-03 PH PH12014502453A patent/PH12014502453A1/en unknown
- 2014-11-04 CL CL2014002986A patent/CL2014002986A1/es unknown
- 2014-12-03 CO CO14266920A patent/CO7141413A2/es unknown
-
2015
- 2015-05-19 HK HK15104774.7A patent/HK1203964A1/zh unknown
-
2017
- 2017-12-14 JP JP2017239643A patent/JP2018039849A/ja active Pending
-
2020
- 2020-10-15 CY CY20201100974T patent/CY1123456T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201804398XA (en) | Method for producing rna molecule compositions | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
SG11201408261UA (en) | Syringe | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201407934UA (en) | Camsylate salt |